Q301--VSN 2 Genetic & Esoteric Testing

The purpose of this amendment to the solicitation 36C24220R0017 is to:

This was requirement was previously expected to be 100% SDVOSB set aside. However, after further evaluation it was determined this strategy was not viable. We are now soliciting unrestricted.

To extend the solicitation end date from 2/21/2020 to 2/28/2020 10:00AM.

The period of performance stated in the Pre-solicitation Notice is now changed from 2/1/2020 to 4/1/2020 thru 3/31/2021 with four (4) additional option years.

Solicitation will be posted soon.

THIS AMEMNDMENT MUST BE SUBMITTED WITH YOUR PROPOSAL.

ALL OTHER TERMS AND CONDITIONS REMAIN UNCHANGED AND IN FULL FORCE AND EFFECT.

The purpose of the amendment to the solicitation 36C24220R0017 is to:

1. To extend the solicitation end date from 1/6/2020 to 2/21/2020 10:00AM.

2. The period of performance stated in the Presolicitation Notice is now changed from 2/1/2020 to 4/1/2020 thru 3/31/2021 with four (4) additional option years.

3. Solicitation will be posted soon.

THIS AMEMNDMENT MUST BE SUBMITTED WITH YOUR PROPOSAL.

ALL OTHER TERMS AND CONDITIONS REMAIN UNCHANGED AND IN FULL FORCE AND EFFECT.

See attached.

Description of Services

The Contractor shall provide a full range of Prognostics, Molecular Diagnostics, and Therapeutic referral laboratory services for the Veterans Integrated Service Network 2, herein after designated as VISN 2 South. VISN 2 South is comprised of the five (5) VA medical center facilities listed below:

JJP VA Medical Center Bronx, NY

VA New Jersey Health Care System

VA Hudson Valley Healthcare System

VA NY Harbor Healthcare System

Northport VA Medical Center

Basic services shall include the transportation of clinical laboratory specimens to the Contractor s laboratory(s), performance of analytical testing as defined by the Contractor s reference test manual, reporting of analytical test results, and consultative services as required to provide the full scope of its laboratory operations for VISN 2 South.

The reference laboratory must be licensed/accredited by the College of American Pathologists, the Nuclear Regulatory Commission, and Center for Disease Control, Medicare and/or other state regulatory agencies as mandated by federal and state statutes. In addition, the Laboratory must be certified as meeting the requirements of the Clinical Laboratory Improvement Act of 1988.

Period of performance is estimated as:

Base period: 1 February 2020 31 February 2021

Option period 1: 1 February 2021 31 February 2022

Option period 2: 1 February 2022 31 February 2023

Option period 3: 1 February 2023 31 February 2024

Option period 4: 1 February 2024 31 February 2025

Solicitation will be posted in 15 Days from this notice.